David C. Stump
Known title: DirectorCIK: 0001191235
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
MGNX mentioned in medical stock sector review. MacroGenics was included in a recent Yahoo Finance article examining the performance of medical stocks this year. The stock is currently trading near its 52-week low, with technical indicators showing weakness near key support levels. This context highlights the broader sector trends affecting the company's valuation.
Transaction History
| RGNX | ▲ Buy | Grant | 9,807 | $0 | 5/29/2026 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 3,750 | — | 5/18/2026 | View on chart |
| RGNX | ▲ Buy | Grant | 7,768 | $0 | 5/30/2025 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 6,500 | — | 5/20/2025 | View on chart |
| RGNX | ▲ Buy | Grant | 4,790 | $0 | 5/31/2024 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 4,500 | $0 | 5/20/2024 | View on chart |
| RGNX | ▲ Buy | Grant | 3,486 | $0 | 6/2/2023 | View on chart |
| RGNX | ▲ Buy | Grant | 3,010 | $0 | 6/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
RGNX Reports Positive 3-Year Data and Settles Patent Litigation
RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.
RGNX Reports Positive 3-Year Data and Settles Patent Litigation. RGNX presented three‑year data showing most NPDR patients improved by more than two steps on the DRSS, with no vision‑threatening events. The company also shared durability results for Surabgene Lomparvovec at the Retina Society meeting. In addition, RGNX settled all Elevidys patent disputes with Sarepta for $39 million and agreed to drop further litigation. These developments highlight progress in both clinical and legal fronts.